Clinical trial
A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of…
NCT00384800 · Far Eastern Memorial Hospital, Other · Unknown status
Key facts
| NCT number | NCT00384800 |
|---|---|
| Title | A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC) |
| Lead sponsor | Far Eastern Memorial Hospital, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular |
| Intervention type | Drug |
| Interventions | Thalidomide(THADO), Tegafur/Uracil(UFUR) |
| Enrollment | 41 |
| Start date | Sep 1, 2006 |
| First posted | Oct 6, 2006 |
| Last update posted | Feb 9, 2009 |
| Countries | Taiwan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: